

REGISTERED NUMBER: 08340031 (England and Wales)

AXOL BIOSCIENCE LTD

Unaudited Financial Statements

for the Year Ended 31 December 2017

Contents of the Financial Statements
for the Year Ended 31 December 2017

	Page
Company Information	1
Accountants' Report	2
Balance Sheet	3
Notes to the Financial Statements	5

AXOL BIOSCIENCE LTD

Company Information
for the Year Ended 31 December 2017

Directors:

Y Shi
S Kumar
Dr J S Milner

Registered office:

Suite 8 The Science Village Building
Chesterford Park
Little Chesterford
Saffron Walden
Cambridgeshire
CB10 1XL

Registered number:

08340031 (England and Wales)

Accountants:

The MPA Group Limited
Mercers Manor Barns
Sherington
Buckinghamshire
MK16 9PU

Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Axol Bioscience Ltd

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Axol Bioscience Ltd for the year ended 31 December 2017 which comprise the Profit and Loss Account, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at <http://www.accaglobal.com/rulebook>.

This report is made solely to the Board of Directors of Axol Bioscience Ltd, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Axol Bioscience Ltd and state those matters that we have agreed to state to the Board of Directors of Axol Bioscience Ltd, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at <http://www.accaglobal.com/factsheet163>. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Axol Bioscience Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Axol Bioscience Ltd. You consider that Axol Bioscience Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Axol Bioscience Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

The MPA Group Limited
Mercers Manor Barns
Sherington
Buckinghamshire
MK16 9PU

Date:

Balance Sheet
31 December 2017

	Notes	31.12.17 £	£	31.12.16 £	£
Fixed assets					
Intangible assets	4		113,583		224,804
Tangible assets	5		<u>87,383</u>		<u>99,865</u>
			200,966		324,669
Current assets					
Stocks	6	105,053		103,453	
Debtors	7	596,902		238,817	
Cash at bank and in hand		<u>2,104,364</u>		<u>337,288</u>	
		2,806,319		679,558	
Creditors					
Amounts falling due within one year	8	<u>373,217</u>		<u>256,857</u>	
Net current assets			2,433,102		422,701
Total assets less current liabilities			2,634,068		747,370
Creditors					
Amounts falling due after more than one year	9		<u>130,934</u>		<u>161,087</u>
Net assets			2,503,134		586,283
Capital and reserves					
Called up share capital			127,589		89,775
Share premium			5,299,919		2,312,652
Retained earnings			<u>(2,924,374)</u>		<u>(1,816,144)</u>
Shareholders' funds			2,503,134		586,283

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

Balance Sheet - continued
31 December 2017

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors on 30 August 2018 and were signed on its behalf by:

Y Shi - Director

Notes to the Financial Statements
for the Year Ended 31 December 2017

1. **Statutory information**

Axol Bioscience Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **Accounting policies**

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

Amortisation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

Agreements - at varying rates on cost

Development Fees - 33% on cost

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Laboratory Equipment - at varying rates on cost

Office Equipment - 33% on cost

Fixtures & Fittings - 20% on cost

Computer equipment - 33% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2017

2. **Accounting policies - continued**

Research and development

Research and development research expenditure is written off to the profit and loss account in the year in which it is incurred. Development expenditure is written off in the same way unless the directors are satisfied as to the technical, commercial and financial viability of individual projects. In this situation, the expenditure is deferred and amortised over the period during which the company is expected to benefit. Capitalised development expenditure is stated at cost less accumulated amortisation and impairment losses. Development costs capitalised are amortised from the date at which the product sales commence, on a straight line basis over their expected useful life.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. **Employees and directors**

The average number of employees during the year was 19 (2016 - 18) .

4. **Intangible fixed assets**

	Development costs £	Agreements £	Totals £
Cost			
At 1 January 2017	551,462	66,123	617,585
Additions	-	22,429	22,429
At 31 December 2017	551,462	88,552	640,014
Amortisation			
At 1 January 2017	371,501	21,280	392,781
Amortisation for year	118,254	15,396	133,650
At 31 December 2017	489,755	36,676	526,431
Net book value			
At 31 December 2017	61,707	51,876	113,583
At 31 December 2016	179,961	44,843	224,804

Notes to the Financial Statements - continued
for the Year Ended 31 December 2017

5. **Tangible fixed assets**

	Laboratory Equipment £	Office Equipment £	Fixtures & Fittings £	Computer equipment £	Totals £
Cost					
At 1 January 2017	178,383	748	40,396	14,076	233,603
Additions	24,475	244	15,581	13,110	53,410
At 31 December 2017	202,858	992	55,977	27,186	287,013
Depreciation					
At 1 January 2017	115,775	541	9,425	7,997	133,738
Charge for year	51,170	112	9,832	4,778	65,892
At 31 December 2017	166,945	653	19,257	12,775	199,630
Net book value					
At 31 December 2017	35,913	339	36,720	14,411	87,383
At 31 December 2016	62,608	207	30,971	6,079	99,865

6. **Stocks**

	31.12.17 £	31.12.16 £
Raw materials	105,053	103,453

7. **Debtors: amounts falling due within one year**

	31.12.17 £	31.12.16 £
Trade debtors	151,108	68,165
Other debtors	158,933	19,903
Debtors Revaluation	(396)	14,399
Tax	-	61,319
VAT	91,477	14,796
Prepayments and accrued income	123,899	17,693
Prepayments	71,881	42,542
	596,902	238,817

8. **Creditors: amounts falling due within one year**

	31.12.17 £	31.12.16 £
Finance leases	3,005	22,923
Trade creditors	128,035	88,654
Social security and other taxes	21,368	13,650
Provision for bad debt	731	-
Other creditors	48,491	1,969
Creditors Revaluation	(109)	8,296
Accruals and deferred income	86,932	86,932
Accrued expenses	84,764	34,433
	373,217	256,857

Notes to the Financial Statements - continued
for the Year Ended 31 December 2017

9. **Creditors: amounts falling due after more than one year**

	31.12.17	31.12.16
	£	£
Bank loans - 1-2 years	55,802	-
Finance leases	2,688	1,710
Accruals and deferred income	72,444	159,377
	<u>130,934</u>	<u>161,087</u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.